Anaesthesia
Conditions
Interventions
All patients receive a dose of intrathecal prilocaine predetermined by the up
and down sequential allocation.
Median effective dose
Total hip arthroplasty
Sponsors
Reinier de Graaf Groep
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:;- ASA I to III - 18y or older - Primary uncemented THA with anterior approach - Willing to participate - Speaking Dutch language
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study:;- Hypersensitivity to local anesthetics or any of the other excipients of prilocaine - Any other contraindications relate to intrathecal anesthesia - CNS disease, e.g. meningitis, tumor, poliomyelitis, cerebral hemorrhage - Spinal stenosis and diseases or recent trauma to the cervical column - Sepsis - Pernicious anemia with symptoms related to cervical degradation - Pyogenic infections of the skin close to the injection site - Cardiogenic or hypovolemic shock - Disturbance in coagulation or treatment with anti-coagulants - Patient is participating in a medicinal study - Noncompliant to intrathecal anesthesia - Patients who are incompetent to decide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of the ED50 (95%CI) of prilocaine administered intrathecally in THA with anterior approach that allows direct post-operative mobilization and will accommodate sufficient anesthesia during surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. | — |
Countries
The Netherlands
Outcome results
None listed